用贝那利珠单抗治疗中重度特应性皮炎：HILLIER 研究结果简明摘要。

IF 2.7 4区医学 Q3 IMMUNOLOGY

Immunotherapy Pub Date : 2024-01-01 Epub Date: 2024-05-02 DOI:10.2217/imt-2023-0319

Emma Guttman-Yassky, Lila Bahadori, Laura Brooks, Ken L Clark, Hanna Grindebacke, Calvin N Ho, Rohit Katial, Tuyet-Hang Pham, Claire Walton, Catherine J Datto

引用次数: 0

摘要

摘要：特应性皮炎（AD）是一种慢性（持续时间较长）皮肤病，患者会出现干燥、瘙痒和红肿的斑点，还会伴有疼痛，并随时发作。有些 AD 患者体内有大量嗜酸性粒细胞（一种白细胞），这与病情加重有关。医护人员开具的药膏和乳液可减轻 AD 的症状。对有些人来说，这些药膏和乳液不起作用。本拉珠单抗注射液是一种可以减少和清除嗜酸性粒细胞的药物。一项名为 "希勒"（HILLER）的临床试验对苯拉利珠单抗进行了测试，以观察在减少或清除嗜酸性粒细胞后，AD的症状是否会有所改善。本文将解释在HILLIER研究中，苯拉利珠单抗是如何减少嗜酸性粒细胞的，以及它对AD症状的影响：研究人员报告的主要结论是什么？然而，与安慰剂相比，本拉珠单抗在AD的体征、症状或严重程度方面没有显示出治疗效果。本拉珠单抗的耐受性和安全性与之前的研究结果一致。在接受本拉珠单抗或安慰剂治疗的患者中，最常报告的五种副作用是COVID-19感染、上呼吸道感染、头痛、淋巴结肿大和红眼病（结膜炎）：本拉珠单抗可降低血液中嗜酸性粒细胞的数量，但不会改善急性髓细胞白血病的症状，而且耐受性良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunotherapy 医学-免疫学

CiteScore

5.00

自引率

3.60%

发文量

113

审稿时长

6-12 weeks

期刊介绍： Many aspects of the immune system and mechanisms of immunomodulatory therapies remain to be elucidated in order to exploit fully the emerging opportunities. Those involved in the research and clinical applications of immunotherapy are challenged by the huge and intricate volumes of knowledge arising from this fast-evolving field. The journal Immunotherapy offers the scientific community an interdisciplinary forum, providing them with information on the most recent advances of various aspects of immunotherapies, in a concise format to aid navigation of this complex field. Immunotherapy delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this vitally important area of research. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.